Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Earning call

<< Previous

Bullboard Posts

Next >>

Comment by Joemareon Apr 04, 2024 8:54am

126 Views

Post# 35969936

RE:Earning call

Zero expectations. They won't deliver. Nothing will have moved. Bunch of loser executives. Fours years too late. They have drained this company dry. How can a bozo like the president earn 2M$ per year and deliver RED on his corporate scorecard? He would have been fired a long time ago at Pfizer.

<< Previous

Bullboard Posts

Next >>

Get a better understanding of the psychology of options trading